ADCX-020

ADCX-020 is a novel antibody-drug conjugate (ADC) developed by Adcytherix for the treatment of cancer. It utilizes a proprietary payload distinct from conventional ADCs, which primarily rely on tubulin or topoisomerase 1 inhibitors. The molecular design of ADCX-020 incorporates innovation in both payload structure and drug-antibody conjugation approach, with the aim of overcoming resistance to existing ADC payloads and expanding the therapeutic scope to tumor types currently lacking effective targeted therapies. The program is positioned as a next-generation ADC candidate, intended for indications in oncology where ADC resistance and tumor heterogeneity present major unmet needs[5][7][9][12][13].